Business Description
Eli Lilly and Co
NAICS : 325412
SIC : 2834
ISIN : US5324571083
Compare
Compare
Traded in other countries / regions
LLY.ArgentinaLLYC.AustriaLILY34.BrazilLLY.FranceLLY.GermanyLLY.MexicoLLY.SwitzerlandLEL.UKLLY.USA IPO Date
1970-07-09Description
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.19 | |||||
| Equity-to-Asset | 0.21 | |||||
| Debt-to-Equity | 1.69 | |||||
| Debt-to-EBITDA | 2.34 | |||||
| Interest Coverage | 20.91 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 7.11 | |||||
| Beneish M-Score | -2.38 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 9.8 | |||||
| 3-Year EBITDA Growth Rate | 9.1 | |||||
| 3-Year EPS without NRI Growth Rate | 11.6 | |||||
| 3-Year FCF Growth Rate | 11 | |||||
| 3-Year Book Growth Rate | 60.3 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 29.7 | |||||
| Future 3-5Y Total Revenue Growth Rate | 12.41 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 37.87 | |||||
| 9-Day RSI | 50.86 | |||||
| 14-Day RSI | 58.99 | |||||
| 6-1 Month Momentum % | 3.02 | |||||
| 12-1 Month Momentum % | 20.04 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.3 | |||||
| Quick Ratio | 1.02 | |||||
| Cash Ratio | 0.23 | |||||
| Days Inventory | 241.72 | |||||
| Days Sales Outstanding | 89.17 | |||||
| Days Payable | 102.96 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.99 | |||||
| Dividend Payout Ratio | 0.65 | |||||
| 3-Year Dividend Growth Rate | 15 | |||||
| Forward Dividend Yield % | 1.06 | |||||
| 5-Year Yield-on-Cost % | 1.9 | |||||
| 3-Year Average Share Buyback Ratio | 0.3 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 77.67 | |||||
| Operating Margin % | 26.4 | |||||
| Net Margin % | 20.54 | |||||
| ROE % | 57.11 | |||||
| ROA % | 11.65 | |||||
| ROIC % | 18.61 | |||||
| ROC (Joel Greenblatt) % | 67.51 | |||||
| ROCE % | 19.94 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 68.8 | |||||
| Forward PE Ratio | 49.02 | |||||
| PE Ratio without NRI | 68.8 | |||||
| Shiller PE Ratio | 86.39 | |||||
| Price-to-Owner-Earnings | 118.84 | |||||
| PEG Ratio | 3.49 | |||||
| PS Ratio | 13.9 | |||||
| PB Ratio | 36.12 | |||||
| Price-to-Tangible-Book | 14193 | |||||
| Price-to-Free-Cash-Flow | 101.67 | |||||
| Price-to-Operating-Cash-Flow | 61.16 | |||||
| EV-to-EBIT | 63.24 | |||||
| EV-to-Forward-EBIT | 46.24 | |||||
| EV-to-EBITDA | 51.9 | |||||
| EV-to-Forward-EBITDA | 39.9 | |||||
| EV-to-Revenue | 15.15 | |||||
| EV-to-Forward-Revenue | 13.38 | |||||
| EV-to-FCF | 110.79 | |||||
| Price-to-Projected-FCF | 5.68 | |||||
| Price-to-Median-PS-Value | 2.97 | |||||
| Price-to-Peter-Lynch-Fair-Value | 4.02 | |||||
| Price-to-Graham-Number | 201.8 | |||||
| Earnings Yield (Greenblatt) % | 1.58 | |||||
| Forward Rate of Return (Yacktman) % | 18.15 |
Balance Sheet Breakdown
Cashflow Statement Breakdown
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:LLY
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
Eli Lilly and Co Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 27,691.4 | ||
| EPS (TTM) ($) | 6.189 | ||
| Beta | 0.44 | ||
| Volatility % | 27.73 | ||
| 14-Day RSI | 58.99 | ||
| 14-Day ATR ($) | 10.019503 | ||
| 20-Day SMA ($) | 429.471 | ||
| 12-1 Month Momentum % | 20.04 | ||
| 52-Week Range ($) | 283.11 - 454.95 | ||
| Shares Outstanding (Mil) | 949.27 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Eli Lilly and Co Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
Eli Lilly and Co Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Eli Lilly and Co Frequently Asked Questions
What is Eli Lilly and Co(LLY)'s stock price today?
The current price of LLY is $425.79. The 52 week high of LLY is $454.95 and 52 week low is $283.11.
When is next earnings date of Eli Lilly and Co(LLY)?
The next earnings date of Eli Lilly and Co(LLY) is 2023-08-08.
Does Eli Lilly and Co(LLY) pay dividends? If so, how much?
The Dividend Yield %  of Eli Lilly and Co(LLY) is 0.99% (As of Today), Highest Dividend Payout Ratio of Eli Lilly and Co(LLY) was 0.89. The lowest was 0.44. And the median was 0.57. The  Forward Dividend Yield % of Eli Lilly and Co(LLY) is 1.06%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
